1103 Results for "

Bioavailability

" in MedChemExpress (MCE) Product Catalog:
Products (1103)

1103 Results for "Bioavailability" in MCE Product Catalog:

21
21 Cited Publications
Cat. No.: HY-100626
CAS No.: 2012607-27-9
Purity:  99.75%
Target:  

WNK Kinase

Research Areas:  

Cancer

WNK463 is an orally bioavailable pan-With-No-Lysine (K) (WNK)-kinase inhibitor with IC50s of 5 nM, 1 nM, 6 nM, and 9 nM for WNK1, WNK2, WNK3, and WNK4, respectively .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-112929
CAS No.: 1809427-19-7
Purity:  99.83%
Target:  

Phosphatase

Research Areas:  

Cancer

DT-061 is an orally bioavailable activator of protein phosphatase 2A (PP2A) and could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-15727
CAS No.: 1047644-62-1
Purity:  99.53%
Synonyms: GSK2110183; LAE002
Target:  

Akt PKC ROCK

Research Areas:  

Cancer

Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively .
loading...
    loading...
20
20 Cited Publications
Cat. No.: HY-15727A
CAS No.: 1047645-82-8
Purity:  99.95%
Synonyms: GSK2110183 hydrochloride; LAE002 hydrochloride
Target:  

Akt PKC ROCK

Research Areas:  

Cancer

Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-15823
CAS No.: 944808-88-2
Purity:  99.93%
Research Areas:  

Cancer

CAY10566 is a potent, orally bioavailable and selective stearoyl-CoA desaturase1 (SCD1) inhibitor with IC50s of 4.5 and 26 nM in mouse and human enzymatic assays, respectively. CAY10566 also shows excellent cellular activity in blocking the conversion of saturated long-chain fatty acid-CoAs (LCFA-CoAs) to monounsaturated LCFA-CoAs in HepG2 cells (IC50=7.9 nM or 6.8 nM) .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15287
CAS No.: 159989-64-7
Purity:  98.74%
Synonyms: AG1341
Target:  

HIV Protease HIV

Research Areas:  

Infection Cancer

Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15287A
CAS No.: 159989-65-8
Purity:  98.93%
Synonyms: AG 1343 Mesylate
Target:  

HIV Protease HIV

Research Areas:  

Infection Cancer

Nelfinavir Mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir Mesylate (AG 1343 Mesylate) is a broad-spectrum, anticancer agent .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-P0025
CAS No.: 143205-42-9
Synonyms: (Melle-4)cyclosporin; SDZ NIM811
NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15532
CAS No.: 891494-63-6
Purity:  99.81%
Synonyms: MK-8776
Research Areas:  

Cancer

SCH900776 (MK-8776) is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with an IC50 of 3 nM. SCH900776 shows 50- and 500-fold selectivity over CDK2 and Chk2, respectively .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-111925
CAS No.: 2361241-23-6
Purity:  99.91%
Target:  

TRP Channel

Research Areas:  

Cardiovascular Disease

BI-749327 is a potent, high selectivity and orally bioavailable TRPC6 antagonist, with IC50s of 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6, respectively. BI-749327 is 85-fold more selective for mouse TRPC6 than TRPC3 and 42-fold versus TRPC7 .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-10480
CAS No.: 1000413-72-8
Purity:  98.97%
Synonyms: TAK-875
Research Areas:  

Metabolic Disease

Fasiglifam (TAK-875) is a potent, selective and orally bioavailable GPR40 agonist with EC50 of 72 nM.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-50682
CAS No.: 603148-36-3
Synonyms: TTP488; PF-04494700
Target:  

Amyloid-β

Research Areas:  

Neurological Disease Cancer

Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-101117
CAS No.: 2083627-02-3
Purity:  99.56%
Research Areas:  

Cancer

EED226 is a polycomb repressive complex 2 (PRC2) inhibitor, which binds to the K27me3-pocket on embryonic ectoderm development (EED) and shows strong antitumor activity in xenograft mice model . EED226 is a potent, selective, and orally bioavailable EED inhibitor . EED226 inhibits PRC2 with an IC50 of 23.4 nM when the H3K27me0 peptide is used as a substrate in the in vitro enzymatic assays .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-13241A
CAS No.: 862505-00-8
Synonyms: LY2228820
Target:  

p38 MAPK Autophagy

Research Areas:  

Cancer

Ralimetinib is an ATP-competitive p38α and p38β MAPK inhibitor with an IC50 of 5.3 nmol/L against human p38α and an IC50 of 3.2 nmol/L against human p38β. Ralimetinib slows tumor growth in preclinical in vivo cancer models, exhibits oral bioavailability in mice, and achieves sustained target inhibition for 4 to 8 h. Ralimetinib is applicable for research on melanoma, non-small cell lung cancer, ovarian cancer, glioma, multiple myeloma, breast cancer, renal cancer, and head and neck squamous cell carcinoma .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-12839
CAS No.: 1006378-90-0
Purity:  99.58%
Target:  

p38 MAPK Autophagy

Research Areas:  

Inflammation/Immunology

p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-15185
CAS No.: 1290543-63-3
Purity:  99.78%
Synonyms: PF-3084014
Target:  

γ-secretase Apoptosis

Research Areas:  

Neurological Disease Cancer

Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-15185B
CAS No.: 1962925-29-6
Purity:  99.63%
Synonyms: PF-3084014 dihydrobromide; PF-03084014 dihydrobromide
Target:  

γ-secretase Apoptosis

Research Areas:  

Cancer

Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC50 of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-D0040
CAS No.: 1461-15-0
Synonyms: Fluorexon
Calcein is a fluorescent dye and self-quenching probe, used as an indicator of lipid vesicle leakage, and also as a complexometric indicator for titration of calcium ions with EDTA, and for fluorometric determination of calcium. Calcein cannot directly cross the intact cell membrane of a living cell, unlike Calcein-AM (HY-D0041) which is cell-permeable. Calcein can also be used as a model drug for evaluating efficiency and bioavailability of drug delivery systems .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-101842
CAS No.: 1434639-57-2
Purity:  99.13%
Research Areas:  

Cancer

ND-646 is an orally bioavailable and steric inhibitor of acetyl-CoA carboxylase (ACC) with IC50s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-13246
CAS No.: 1032754-93-0
Purity:  99.29%
Synonyms: GDC-0980; GNE 390; RG 7422
Target:  

PI3K mTOR Apoptosis

Research Areas:  

Cancer

Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?Ki?of 17 nM for mTOR.
loading...
    loading...